Researcher Database | Faculty of Pharmaceutical Sciences Department of Pharmacy | Akira Takaguri |

（Last updated : 2024-07-02 09:30:23）

Visruth.jpg not found

Akira Takaguri

Department / Course Hokkaido University of Science Faculty of Pharmaceutical Sciences Department of Pharmacy

Job Associate Professor

Academic background
2009/03 Degree Acquisition
2006/03 Degree Acquisition

Present specialized field
Pharmacology

Book and thesis
Papers	Epalrestat enhances MTS reduction activity independent of cell numbers in bovine aortic endothelial cells Pharmacology and Pharmacy (Co-authored) 2023/02
Papers	Rational design and structure-activity relationship studies reveal new esterified C20-diterpenoid alkaloid analogues active against MCF-7 human breast cancer cells (Co-authored) 2023
Papers	The role of tribbles homolog 2 in vascular smooth muscle cell proliferation (Co-authored) 2023
Papers	Role of Erythropoiesis-Stimulating Agents in Cardiovascular Protection in CKD Patients: Reappraisal of Their Impact and Mechanisms Cardiovascular Drugs Ther (Co-authored) 2022/02
Papers	Involvement of circadian clock gene BMAL1 in doxorubicin-induced inflammation in vascular smooth muscle cells Pharmacology and Pharmacy 12 (11) (Co-authored) 2021/12
Display All（8）

Academic conference presentation
2014/11	A DISINTEGRIN AND METALLOPROTEASE 17, A POTENTIAL MEDIATOR OF INTERLEUKIN-1Α DEPENDENT INSULIN RESISTANCE IN L6 RAT SKELETAL MUSCLE CELLS (10th IDF-WPR and 6th AASD Scientific Meeting 2014)
2011	Constitutive stimulation of vascular smooth muscle cells by Angiotensin II derived from adenovirus encoding a furin-cleavable fusion membrane protein (The Federation of American Societies for Experimental Biology (Washington USA))
2011	Vascular Selective ADAM17 Silencing Prevented Medial Hypertrophy and Perivascular Fibrosis Induced by Angiotensin II Infusion (High Blood Pressure Research 2011 Scientific Sessions (Orlando USA))
2011	Vascular Selective ADAM17 Silencing Prevented Medial Hypertrophy and Perivascular Fibrosis Induced by Angiotensin II Infusion. (AHA Scientific Sessions (Orlando USA))
2010	ADAM17 is a novel therapeutic target for vascular remodeling. (Gordon Research Conference (Ventura USA))
Display All（13）